Will Shareholders Support The Bristol/Celgene Merger? – An Informa Pharma Intelligence Podcast
Expectations that the $74bn deal will go through are now reinforced by proxy advisor recommendations that shareholders vote in favor of the transaction. Podcast discussion also includes Karyopharm’s selinexor and J&J’s Spravato.
You may also be interested in...
Deal Watch: Editas, BlueRock Ink Cross-Licensing Technology Collaboration
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.
J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray
Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.